Grace Therapeutics (GRCE) 10% Owner Opaleye Buys 15,089 Shares

What Happened
Opaleye Management, Inc., the investment manager associated with Opaleye, L.P. (a reported 10% owner), purchased a total of 15,089 shares of Grace Therapeutics (GRCE) in two transactions. On 2026-09-21 it acquired 9,771 shares at $2.10 each (≈ $20,519) and on 2026-09-23 it acquired 5,318 shares at $2.10 each (≈ $11,168), for a combined cash outlay of about $31,687. These were purchase transactions (code P), which are purchases rather than sales.

Key Details

• Transaction dates and prices:
  • 2026-09-21: 9,771 shares @ $2.10 = $20,519
  • 2026-09-23: 5,318 shares @ $2.10 = $11,168
• Total shares acquired: 15,089; total value: ≈ $31,687.
• Shares owned after the transactions: not specified in the summary provided; the Form 4/A was filed to correct the previously misstated amount in the original Form 4.
• Filing details: Amended Form 4 (Form 4/A) filed 2026-10-01 correcting the amount of securities beneficially owned reported in the original 09/23/2026 filing.
• Footnotes of note:
  • F1: Shares are owned directly by Opaleye, L.P.; Opaleye Management, Inc. is the Fund’s investment manager and may be deemed to beneficially own those shares.
  • F2: Opaleye Management, Inc. disclaims beneficial ownership except to the extent of its pecuniary interest.

Context

• Code P = purchase (open market or private purchase). Purchases by large holders can be viewed as informative, but this filing is by a 10% institutional owner (Opaleye/Opaleye, L.P.), not an individual company executive.
• The amendment corrects the reported beneficial ownership figure; no other derivative or complex transactions (e.g., option exercises, gifts, or tax withholdings) were reported.